FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年5月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | 1 RMB | | 27,553,260 | | 2. 股份分類 | 普通股 | 股份類別 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Insights - The company reported a strong recovery in performance with a 10.10% year-on-year increase in revenue for Q1 2025, reaching 1.541 billion yuan, driven by rapid growth in emerging businesses [4][7] - The net profit attributable to shareholders increased by 15.83% year-on-year to 327 million yuan, with a notable 20.14% growth in non-recurring net profit, indicating effective cost management and improved gross margins in emerging businesses [4][7] - Emerging businesses, including peptides and oligonucleotides, showed impressive growth with revenue increasing over 80% and gross margins improving to 33.05% [7] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 6.468 billion yuan, with a projected year-on-year growth rate of 11.4% [6] - The net profit forecast for 2025 is 1.071 billion yuan, reflecting a 12.9% increase compared to the previous year [6] - The company expects to maintain a stable gross margin of around 43.2% in 2025, with a gradual increase in return on equity (ROE) from 6.0% in 2025 to 6.9% in 2027 [6][7]

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 97.16, compared to the current price of RMB 74.47 [1][10]. Core Insights - The company is experiencing rapid growth in emerging businesses, leading to improved profitability. The focus on polypeptide capabilities and global expansion is expected to drive long-term growth [1][10]. - In Q1 2025, the company reported revenue of RMB 1.54 billion, a 10.10% increase year-on-year, and a net profit attributable to shareholders of RMB 327 million, up 15.83% [10]. - The gross profit margin for Q1 2025 was 42.54%, showing a year-on-year decline of 0.98 percentage points but an increase of 3.28 percentage points quarter-on-quarter [10]. Financial Summary - Revenue projections for 2025-2027 are RMB 6.63 billion, RMB 7.79 billion, and RMB 9.32 billion, respectively, with expected growth rates of 14.2%, 17.5%, and 19.5% [3][5]. - Net profit attributable to shareholders is forecasted to be RMB 1.09 billion in 2025, RMB 1.28 billion in 2026, and RMB 1.53 billion in 2027, reflecting growth rates of 15.1%, 16.8%, and 19.5% [3][5]. - The earnings per share (EPS) for 2025-2027 are projected at RMB 3.03, RMB 3.54, and RMB 4.23, respectively [3][10]. Business Performance - The small molecule CDMO business remained stable, while emerging business revenues grew over 80% year-on-year, with a gross profit margin of 33.05%, up 15.75 percentage points from 2024 [10]. - The company secured a total order backlog of USD 1.052 billion, representing a growth of over 20% year-on-year, ensuring stable revenue growth [10]. - The European R&D and pilot base commenced operations in August 2024, contributing to the expansion of the company's capabilities [10].

Core Insights - The company reported a revenue of 1.541 billion yuan for Q1 2025, representing a year-on-year increase of 10.10% but a quarter-on-quarter decrease of 7.4% [1] - The net profit attributable to shareholders was 327 million yuan, up 15.8% year-on-year and up 36.9% quarter-on-quarter, indicating a significant improvement in profitability [1] - The company’s operating efficiency and scale effects are believed to be the main drivers behind the better-than-expected performance [1] Financial Performance - The net profit margin for Q1 2025 was 21.2%, an increase of 1.0 percentage points year-on-year and 6.9 percentage points quarter-on-quarter [2] - The gross profit margin remained stable, with a year-on-year decrease of 1.0 percentage points but a quarter-on-quarter increase of 3.3 percentage points [2] - Total sales, management, and R&D expenses amounted to 366 million yuan, down 5.4% year-on-year and 26.4% quarter-on-quarter, leading to a reduced expense ratio of 23.7% [2] Business Development - The small molecule business showed resilience with stable revenue and a high gross margin of 45.17% [2] - Emerging businesses, including peptides, oligonucleotides, and ADCs, experienced over 80% year-on-year revenue growth in Q1, with a gross margin of 33.05% [2] - The company anticipates 12 PPQ projects in small molecules and 13 in emerging businesses by 2025, with ongoing capacity expansion in peptide production [2] Global Capacity Expansion - The Sandwich Site in the UK commenced operations in early August 2024, enhancing the company's capabilities in continuous reaction equipment and advanced manufacturing technologies [3] - Following the site’s launch, the company has secured multiple orders for analysis, process development, and kilogram-level production [3] Profit Forecast and Valuation - The company maintains its profit forecasts for 2025 and 2026, with the current stock price corresponding to a P/E ratio of 24.5x for 2025 and 21.4x for 2026 [4] - The target price is set at 102.00 yuan, implying a potential upside of 37.0% based on a P/E ratio of 33.5x for 2025 and 29.3x for 2026 [4]

Core Viewpoint - The "Quality Return Dual Improvement" initiative launched by the Shenzhen Stock Exchange has been implemented for over a year, with 452 companies participating and focusing on enhancing core business awareness, innovation capabilities, and investor returns [1][2]. Group 1: Company Performance - Companies practicing the "Quality Return Dual Improvement" initiative have shown significant performance growth in 2024, with Changying Precision reporting a revenue of approximately 16.934 billion yuan and a net profit of about 772 million yuan, reflecting increases of 23.28% and 800.24% respectively [1]. - Zhongji Xuchuang achieved a revenue of 23.862 billion yuan and a net profit of approximately 5.171 billion yuan, with year-on-year increases of 122.64% and 137.93% respectively [1]. Group 2: Investor Returns - 452 companies have proposed practical measures to enhance investor returns, including increased cash dividends and share buybacks, with Ningde Times announcing a total cash dividend of 25.372 billion yuan for 2024 and BYD declaring a cash dividend of 12.077 billion yuan [2]. - 132 companies have responded to the new "National Nine Articles" by arranging for quarterly and mid-term dividends, with Ping An Bank implementing a mid-term dividend of 4.774 billion yuan, achieving a payout ratio of 18.4% [2]. Group 3: Market Response - Since the launch of the initiative, 232 companies have conducted share buybacks totaling 32.138 billion yuan, with Kailaiying planning to repurchase shares worth between 600 million and 1.2 billion yuan [2][3]. - Major shareholders and management have shown confidence in future company development through share purchases, with Rongsheng Petrochemical's controlling shareholder increasing holdings by 1.188 billion yuan from January to July 2024 and planning further purchases [3]. Group 4: Market Capitalization - The 452 participating companies represent a total market capitalization of 16.43 trillion yuan, accounting for nearly 50% of the Shenzhen market's total market value, with 334 companies having a market cap exceeding 10 billion yuan [4]. - The market capitalization change of these companies has outperformed the overall Shenzhen market, indicating strong market recognition of the "Quality Return Dual Improvement" concept [4]. Group 5: Innovation and R&D - Companies involved in the initiative have significantly increased their R&D investment as a percentage of revenue, with 18 companies, including iFlytek and Goldwind Technology, winning national science and technology progress awards, representing 45% of the total awarded companies in the Shenzhen market [5]. - The Shenzhen Stock Exchange aims to continue promoting the quality and investment value of listed companies through the "Quality Return Dual Improvement" initiative [5].

Core Viewpoint - 凯莱英 (002821) reported a robust growth in revenue and profit margin for Q1 2025, with a year-on-year revenue increase of 10.1% and a net profit increase of 15.8%, leading to an "overweight" rating from Tianfeng Securities [1][2]. Financial Performance - In Q1 2025, the company achieved a revenue of 1.541 billion yuan and a net profit of 327 million yuan, with gross profit margin and net profit margin at 42.5% and 21.2% respectively [2]. - The net profit growth rate outpaced revenue growth by 5.7 percentage points, indicating effective cost control measures [3]. Cost Control and Efficiency - The company implemented cost reduction and efficiency improvement measures, resulting in a decrease in all expense ratios year-on-year and quarter-on-quarter [3]. - Sales expenses were 44.15 million yuan with a sales expense ratio of 2.9%, down 0.3 percentage points year-on-year and 1.7 percentage points quarter-on-quarter [3]. - Management expenses totaled 184 million yuan with a management expense ratio of 11.9%, down 0.4 percentage points year-on-year and 5.5 percentage points quarter-on-quarter [3]. - R&D expenses were 138 million yuan with a ratio of 8.9%, down 3.2 percentage points year-on-year and 1.1 percentage points quarter-on-quarter [3]. Business Segments - The small molecule CDMO business remained stable with a gross profit margin of 45.17%, and 12 projects expected to reach the PPQ stage in 2025 [3]. - Emerging business revenue grew over 80% year-on-year, with a gross profit margin of 33.05%, indicating a recovery compared to the previous year [3]. - The company plans to add a new OEB5 facility and R&D building to support the growing demand for toxin-linker projects [3]. Employee Incentives - The company launched a restricted stock incentive plan, granting 4.896 million shares at a price of 37.52 yuan per share to 648 individuals, including directors and key personnel [4]. - The plan includes performance-based vesting conditions tied to revenue and profit growth targets from 2025 to 2028 [4]. Profit Forecast and Investment Rating - The company forecasts revenues of 6.617 billion yuan, 7.617 billion yuan, and 8.782 billion yuan for 2025, 2026, and 2027 respectively, with net profits of 1.114 billion yuan, 1.310 billion yuan, and 1.532 billion yuan [5]. - The investment rating remains "overweight" based on the positive financial outlook and growth potential [5].

Core Insights - The global and US innovative drug VC&PE financing amounts are expected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the innovative drug financing environment [1] - The demand for research and development in fields such as peptides and ADCs is strong, leading to an increase in outsourcing needs in these areas [1][2] Macro Perspective - The global innovative drug financing environment is recovering, with significant growth in the demand for innovative research in specific fields like peptides and ADCs, which is expected to enhance the CXO industry's outlook [1] - According to Crunchbase, the VC&PE financing for innovative drugs in 2024 shows positive growth, marking an improvement in the financing environment [1] Micro Perspective - CXO listed companies are seeing a recovery in new orders, with many companies like WuXi AppTec, WuXi Biologics, and others reporting a year-on-year increase of over 20% in new orders [3] - The production capacity of domestic CXO companies is mature, ensuring timely delivery of orders, which is expected to lead to double-digit revenue growth for several companies in 2025 [3] Target Companies - Recommended companies to watch include WuXi AppTec (603259.SH, 02359), WuXi Biologics (02269), WuXi AppTec (02268), Kelun Pharmaceutical (002821.SZ, 06821), and others [4]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price set at 74.47 CNY [7][5]. Core Insights - The company reported a revenue of 1.541 billion CNY for Q1 2025, representing a year-on-year growth of 10.1%, and a net profit of 327 million CNY, up 15.8% year-on-year [1]. - The gross profit margin and net profit margin for Q1 2025 were 42.5% and 21.2%, respectively [1]. - The company has implemented cost reduction and efficiency improvement measures, resulting in a net profit growth rate that outpaced revenue growth by 5.7 percentage points in Q1 2025 [2]. - The small molecule CDMO business showed stable performance with a gross margin of 45.17%, while emerging businesses saw revenue growth exceeding 80% and a gross margin of 33.05% [3]. - A stock incentive plan was introduced, granting 4.896 million shares at a price of 37.52 CNY per share, aimed at enhancing employee motivation and company cohesion [4]. Financial Projections - Revenue projections for 2025-2027 are estimated at 6.617 billion CNY, 7.617 billion CNY, and 8.782 billion CNY, respectively [5]. - The expected net profit for the same period is projected to be 1.114 billion CNY, 1.310 billion CNY, and 1.532 billion CNY [5]. - The report anticipates a consistent increase in revenue and net profit margins over the forecast period [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights significant achievements in cost reduction and efficiency improvement, with a notable increase in net profit margin quarter-on-quarter [6] - Emerging businesses have shown a strong recovery with over 80% year-on-year revenue growth [6] - The company maintains its profit forecast, expecting revenue and net profit growth for the years 2025 to 2027 [6] Financial Performance Summary - For Q1 2025, the company achieved total operating revenue of 1.541 billion yuan, a year-on-year increase of 10.10%, and a net profit attributable to shareholders of 327 million yuan, up 15.83% year-on-year [5] - The gross profit margin for Q1 2025 was 42.54%, a decrease of 0.98 percentage points year-on-year, while the net profit margin recovered to 21.06%, an increase of 1.09 percentage points year-on-year and 6.91 percentage points quarter-on-quarter [6] - The company’s small molecule business maintained stable development, with revenue remaining flat and a gross margin of 45.17% [6] Profit Forecast and Valuation - The company’s projected operating revenue for 2025, 2026, and 2027 is 6.5 billion, 7.3 billion, and 8.2 billion yuan respectively, with net profits of 1.164 billion, 1.410 billion, and 1.673 billion yuan respectively [8][9] - Corresponding P/E ratios are expected to be 23x, 19x, and 16x for the years 2025, 2026, and 2027 [6][9]

Core Insights - Gao Yi Asset Management recently conducted research on a listed company, Kailai Ying, revealing positive financial performance in Q1 2025 [1] Financial Performance Summary - Kailai Ying reported a main revenue of 1.541 billion yuan, an increase of 10.1% year-on-year [1] - The net profit attributable to shareholders was 327 million yuan, reflecting a year-on-year growth of 15.83% [1] - The net profit after deducting non-recurring items was 305 million yuan, up by 20.14% year-on-year [1] - The company's debt ratio stood at 11.58% [1] - Investment income amounted to 10.2752 million yuan, while financial expenses were -44.9396 million yuan [1] - The gross profit margin was reported at 42.54% [1] Company Overview - Gao Yi Asset Management is a prominent private equity fund management company in China, known for its strong research capabilities and large management scale [2] - The firm focuses on capital markets and aims to provide top-notch research support and resources to its investment managers [2] - The investment team consists of over 30 members, including experienced managers and award-winning fund managers from leading fund companies [2] - The company is registered in Shanghai and has teams located in Shenzhen, Shanghai, and Beijing [2]